



Contact Us

Customer Service:
315-461-3008

RRL at Crouse Hospital:
315-470-7391

Visit us on the Web
www.laboratoryalliance.com



LABORATORY ALLIANCE
of Central New York, LLC

Operations Center
113 Innovation Lane • Liverpool, New York 13088
Ph: (315) 410-7000
www.laboratoryalliance.com

2024 OUTREACH Antibiogram

Data Are Percent Susceptible

January 2023 – December 2023

Brian Pavlovitz, MD, Medical Director
Paul A. Granato, PhD, Director, Microbiology
Russell A. Rawling, MS, Microbiology Manager

Choice of Antimicrobial Therapy

A. Empiric Therapy:

Prior to receiving specific susceptibility results, drugs to which organisms are greater than 80% susceptible are generally considered good choices, although patient history, site of infection, and specific pharmacologic properties as they apply to the particular patient must be taken into account.

B. Therapeutic Therapy:

The drug of choice for treatment of an infection is usually the most active drug against the pathogenic organism or the organism most likely to cause infection. Choice of drugs should be modified by site of infection and patient's clinical status regarding allergy, renal function, immune status or pregnancy.

Visit us on the Web
www.laboratoryalliance.com

Organism Display	Number of Isolates*	Ampicillin	Amoxicillin/clavulanate	Ampicillin/subbactam	Piperacillin/tazobactam!	Cefazolin**	Cefoxitin	Cefepime	Ceftazidime	Ceftriaxone	Cefiderocol	Ertapenem	Meropenem	Ciprofloxacin	Levofloxacin	Gentamicin++	Tobramycin	Amikacin	Tetracycline (Doxycycline)	Minocycline	Trimethoprim/sulfamethoxazole (Bactrim)	Nitrofurantoin	Clindamycin	Erythromycin	Azithromycin	Oxacillin+	Penicillin	Vancomycin	Rifampin++	Daptomycin!	Linezolid
ESCHERICHIA COLI	5883	58	86	ND	96/97	90	94	92	92	92	ND	100	100	80	76	92	92	100	80	ND	82	98									
KLEBSIELLA PNEUMONIAE	1239	0	95	ND	90/96	91	96	92	92	92	ND	100	100	88	86	95	94	100	81	ND	89	36									
PROTEUS MIRABILIS	663	83	100	ND	100/100	96	96	98	98	98	ND	80	100	70	70	96	97	100	0	ND	80	0									
ENTEROBACTER CLOACAE COMPLEX	247	0	0	ND	85/87	0	0	97	84	82	ND	94	99	91	85	92	92	100	86	ND	89	45									
KLEBSIELLA OXYTOCA	201	0	97	ND	97/98	80	98	98	97	97	ND	100	100	97	96	97	97	100	95	ND	98	90									
SERRATIA MARCESCENS	156	0	0	ND	100/100	0	26	100	100	100	ND	98	100	95	94	99	55	100	26	ND	99	0									
CITROBACTER KOSERI	94	0	34	ND	100/100	100	98	100	100	100	ND	100	100	100	99	99	100	100	99	ND	99	99									
CITROBACTER FREUNDII	75	0	0	ND	88/90	0	0	99	82	82	ND	97	99	96	93	93	93	100	92	ND	91	97									
MORGANELLA MORGANI	68	0	1	ND	97/97	0	45	97	87	85	ND	98	100	61	60	96	99	99	40	ND	68	0									
PSEUDOMONAS AERUGINOSA	698	NI	NI	NI	96	NI	NI	94	94	NI	ND	NI	93	86	76	NI	100	99	NI	NI	NI	NI									
ACINETOBACT BAUMANII- COMM WIDE	112		81	49				47					56	40	44	73	97			52											
STENOTROPHOMONAS MALTIOPHILIA	65										100				82				100	100											
HAEMOPHILUS INFLUENZAE	52	60	100						100						100			67		67											
STREPTOCOCCUS PNEUMONIAE	31									93					100			59		74		83	40	40		#100	100			100	
BETA STREP GRP A- BLOOD & SOFT TISSUE	132	100								100					89			87					75	73			100	100			100
BETA STREP GRP B- BLOOD & SOFT TISSUE	378	100								100					99			15					40	28			100	100			100
ENTEROCOCCUS SP., VSE	624	93												73	74				0			94	22			92	100		80	100	
ENTEROCOCCUS SP., VRE	76	31												0	0				0			42	0			30	0		ND	100	
STAPH. AUREUS, MSSA	1160													92	93	100			92		97	100	75	65		100	100	100	100	100	
STAPH. AUREUS, MRSA	564													29	30	99			86		84	100	78	13	0		100	100	100	100	
STAPH. SPECIES, COAG.NEG	375													82	82	92			79		75	99	69	39	59		100	99	100	100	
STAPHYLOCOCCUS SAPROPHYTICUS	195													99	100				94		99	99			46		100	100			

* Note: isolates from all sources; urine, blood, respiratory, wound, etc.

! Data is for Enterococcus faecalis only.

!! Pip/Taz data for ENTERICS: 1st % is Susceptible (<=8/4) and 2nd % is Susceptible plus Susceptible Dose Dependent (<=16/4)

** For uncomplicated UI's, Cefazolin MIC results less than or equal to 16 mcg/ml predict susceptibility of the following oral cephalosporins: cefactor, cefdinir, cefpodoxime, cefprozil, cefuroxime and cephalexin.

+ Oxacillin susceptible Staph are also susceptible to other penicillinase resistant penicillins, betaactam/betalactamase inhibitor combinations, cepheims, and carbapenems FDA approved to treat Staph infections.

++ Gentamicin and Rifampin may be used in combination with other drugs against Staph isolates.

100 % were in the intermediate or susceptible range indicating many could be treated for pneumonia with appropriate dosing of an IV penicillin.

NI= drug not active

ND = No data

The percentage in red are greater than or equal to 80% susceptibility, potentially useful for empiric therapy.